Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Team Grant: Human Immunology Initiative: Research Teams - LOI - CIHR-JDRF Pool

University of British Columbia

$20,000.00

Innate and adaptive immune regulation in human type 1 diabetes

EF 2018-19

Résumé
Type 1 diabetes (T1D) is an autoimmune disease that is caused by the immune system mistakenly killing cells in the pancreas which produce insulin. Without insulin, the body cannot regulate blood sugar and this can be life threatening. Insulin can be replaced by daily injections, but this treatment does not replace the natural ability of the pancreas to make insulin only when it is needed, and at the exact level needed. Hence, subjects with T1D still suffer from fluctuating blood sugar and over a lifetime this leads to life-threatening complications. A true cure for T1D requires the immune system to be re-set so it no longer attacks the pancreas, as well as regeneration of the insulin-producing cells. In this project we propose to assemble a cross-Canada team which is uniquely positioned to study both the immune and insulin-producing cells, which are called beta cells. First, we will collect samples of blood from a variety of cohorts (with T1D, another autoimmune disease or healthy controls) as well as data, including data related to sex and gender. We will then use these blood samples to study how different aspects of the immune system change over time in T1D versus non-T1D subjects, and ask how immune changes correlated with beta cell changes. Statistical analysis will reveal whether effects may be different in males versus females, and/or related to gender-based effects. Second, we will study how two promising types of immune cell-based therapies might be applied in T1D. We will study how these immune cell therapies might affect beta cell function/regeneration and develop new ways to apply such therapies as a treatment for T1D. Overall, the proposed research will explore several never-before investigated aspects of T1D biology and take existing therapeutic concepts a step closer to clinical application. We will also create synergy with other on-going international studies in T1D and further strengthen our research capacity in this domain.
Programme
Team Grant: Human Immunology Initiative: Research Teams - LOI - CIHR-JDRF Pool
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
396021
Name
Levings Megan K
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Human Immunology Initiative - Research Teams
Projecttitle
Innate and adaptive immune regulation in human type 1 diabetes
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Team Grant: Human Immunology Initiative: Research Teams - LOI - CIHR-JDRF Pool
Keyworddelim
Biomarkers; Cell Therapy; Immune Regulation; Tissue Immunity; Type 1 Diabetes
Abstract
Type 1 diabetes (T1D) is an autoimmune disease that is caused by the immune system mistakenly killing cells in the pancreas which produce insulin. Without insulin, the body cannot regulate blood sugar and this can be life threatening. Insulin can be replaced by daily injections, but this treatment does not replace the natural ability of the pancreas to make insulin only when it is needed, and at the exact level needed. Hence, subjects with T1D still suffer from fluctuating blood sugar and over a lifetime this leads to life-threatening complications. A true cure for T1D requires the immune system to be re-set so it no longer attacks the pancreas, as well as regeneration of the insulin-producing cells. In this project we propose to assemble a cross-Canada team which is uniquely positioned to study both the immune and insulin-producing cells, which are called beta cells. First, we will collect samples of blood from a variety of cohorts (with T1D, another autoimmune disease or healthy controls) as well as data, including data related to sex and gender. We will then use these blood samples to study how different aspects of the immune system change over time in T1D versus non-T1D subjects, and ask how immune changes correlated with beta cell changes. Statistical analysis will reveal whether effects may be different in males versus females, and/or related to gender-based effects. Second, we will study how two promising types of immune cell-based therapies might be applied in T1D. We will study how these immune cell therapies might affect beta cell function/regeneration and develop new ways to apply such therapies as a treatment for T1D. Overall, the proposed research will explore several never-before investigated aspects of T1D biology and take existing therapeutic concepts a step closer to clinical application. We will also create synergy with other on-going international studies in T1D and further strengthen our research capacity in this domain.
Competitiondate
201810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Levings, Megan K; Crome, Sarah A; Panagiotopoulos, Constadina; Ritz, Stacey A; Verchere, Bruce C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $20,000~ $0~